Danielle Ternyila

In an interview with Targeted Oncology, Bianca D. Santomasso, MD, PhD, discussed the challenges with treating patients who develop neurotoxicity following treatment with new CAR T cells following her talk at the 2019 SOHO Annual Meeting. She also highlighted how the CAR T cells are changing the treatment landscape for patients with lymphomas.

In an interview with Targeted Oncology, Davis S. Snyder, MD, discussed the treatment approaches for patients with MF who are candidates for SCT, as well as prognostic scoring systems that can help determine a patient’s likelihood of response to transplant.

In an interview with Targeted Oncology, Mark Yarchoan, MD, discussed the treatment options available for patients with liver-only HCC who are not eligible for surgery or transplant. He also highlighted the different treatment options that are under investigation now for patients with HCC in the first- and second-line settings.

In an interview with Targeted Oncology, Kathleen Moore, MD, discussed the data surrounding mirvetuximab soravtansine in this patient population and the plans to reevaluate the ADC following the results from the FORWARD I/GOG 3011 clinical trial. She also highlighted other areas of investigation for women with platinum-resistant ovarian cancer.

A New Drug Application has been accepted and granted priority review by the FDA to the investigational agent selumetinib for the treatment of patients ≥3 years old with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas, according to a press release from AstraZeneca and Merck.

In an interview with Targeted Oncology, Willemina R. Geurts-Giele, PhD, discussed the accuracy of detecting MET exon 14 skipping mutations in patients with NSCLC with DNA-based NGS panels. These findings were presented at The Association for Molecular Pathology Annual Meeting and Expo.

In an interview with Targeted Oncology, Scott T. Tagawa, MD, discussed the findings from the TROPHY-U-O1 trial presented at the 2019 ESMO Congress and shared his thoughts on the next steps for sacituzumab govitecan.

In an interview with Targeted Oncology, John Simmons, PhD, discussed the potential role of liquid biopsy assays in predicting response to immune checkpoint inhibitor therapy for patients with cancer. He also highlighted other liquid biopsy assays that are in development for detecting MSI.

At the 2019 Association for Molecular Pathology Annual Meeting and Expo, Adam Fisch, MD, PhD, presented a unique patient case where a patient with acute myeloid leukemia harboring a <em>FLT3</em>-TKD mutation lost the mutation following relapse on gilteritinib.<br /> &nbsp;

In an interview with&nbsp;Targeted Oncology, Alan Bryce, MD, discussed the significance of the data from PROfound for men with mCRPC. He also highlighted findings from the CARD trial and where the field is headed in terms of targeted therapies versus chemotherapies.

In October 2019, the FDA approved a new treatment option for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer, as well as a new dosing regimen for patients receiving moderately emetogenic chemotherapy. Additionally, the FDA granted breakthrough therapy designations to 2 therapies, as well as an orphan drug designation, a priority review, and 2 fast track designations.

Topline results from Re-MIND, an observational retrospective study, demonstrated that the combination of tafasitamab with lenalidomide had a statistically significant and superior objective response rate compared with lenalidomide monotherapy in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for high-dose chemotherapy and stem cell transplant, announced MorphoSys AG, the manufacturer of tafasitamab, in a press release.

In an interview with&nbsp;<em>Targeted Oncology</em>, Catherine Sinclair, MD, discussed the importance of early detection in patients with thyroid cancer. She also highlighted surgical decisions for these patients and how she makes these choices for each patient.

In an interview with&nbsp;Targeted Oncology, Hannah Linden, MD, discussed the current treatment landscape during Breast Cancer Awareness Month. She also highlighted the value of liquid biopsy, tissue biopsy, and imaging techniques in this space for identifying patients with targetable mutations and how these assays and techniques can further impact treatment and outcomes of these patients.

In an interview with <em>Targeted Oncology</em>, Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discussed the updated OS results from the FLAURA trial and evaluated the role of osimertinib in patients with <em>EGFR-</em>mutant NSCLC. He also highlighted some next steps with research for this patient population, such as the potential combination of osimertinib with other agents.

In an interview with <em>Targeted Oncology</em>, Dr. Miles, discussed the importance of early detection for patients with thyroid cancer. He also highlighted how the treatment options differ for patients with disease that is caught early on versus those with more advanced and aggressive diseases, such as anaplastic thyroid cancer.<br /> &nbsp;

During a&nbsp;Targeted Oncology&nbsp;tweet chat, Naveen Pemmaraju, MD, and Aaron Gerds, MD, MS, led a discussion on a patient case with myelofibrosis. They reviewed the options from a Twitter poll and how they would approach treatment of this particular patient.

In an interview with Targeted Oncology, Amit Singal, MD, MS,&nbsp;discussed issues with surveillance in patients with NASH, with or without cirrhosis. He also highlighted how combatting these issues can help improve the survival of patients with NASH-related HCC.

In an interview with Targeted Oncology, Kristen M. Pettit, MD, discussed the data supporting the FDA&rsquo;s fast track designation of the novel agent IMG-7289 for the treatment of patients with MF.

In an interview with&nbsp;Targeted Oncology, Luis Paz-Ares, MD, PhD, discussed the findings for the CASPIAN trial that were presented at the 2019 ESMO Congress. He also addressed what next steps are necessary to further develop the durvalumab combination in this setting.&nbsp;

In an interview with <em>Targeted Oncology</em>, Daniel Catenacci, MD, discussed the clinical trials supporting immunotherapeutic options for patients with GEJ cancer. He also highlighted how physicians can sequence these agents appropriately in their patients.

In an interview with <em>Targeted Oncology</em>, Michael A. Choti, MD, MBA discussed the treatment landscape for patients with pancreatic cancer, as well as how the role of neoadjuvant chemotherapy in this space is changing. He highlights advantages of neoadjuvant strategies, and also some other treatment options for patients with pancreatic cancer.

In an interview with <em>Targeted Oncology</em>, Kasi, assistant professor of oncology and senior associate consultant in the Division of Hematology/Oncology at the University of Iowa, Holden Comprehensive Cancer Center, discussed the current role and utility of liquid biopsy in colorectal cancer, and what he&rsquo;s looking forward to bringing up during the 2019 ISGIO Annual Conference.

Following the 2019 ESMO Congress, experts across various fields highlighted some next steps and how these treatment options will improve the treatment landscape for patients with ovarian, lung, breast, GI, or GU cancers. Overall, the abstracts presented at this year&rsquo;s meeting will change the treatment paradigm in a number of patient populations.

In September 2019, the FDA approved new treatment options for patients with endometrial carcinoma, prostate cancer, and multiple myeloma. The FDA also expanded the indication for the Cologuard noninvasive screening test for colorectal cancer. During the month there were 2 breakthrough therapy designations, 2 fast track designations, 1 orphan drug designation, and 1 priority review granted.

Umbralisib and ublituximab in combination with pembrolizumab was well tolerated among patients with relapsed/refractory chronic lymphocytic leukemia and Richter&rsquo;s transformation, according to a phase I/II trial presented at the 18th International Workshop on CLL. Responses were durable in high-risk patients who are BTK-refractory, including 2 complete responses in patients with RT.

In an interview with&nbsp;Targeted Oncology, Tetsuya Mitsudomi, MD, summarized the major areas under investigation for the treatment of patients with lung cancer and highlighted key findings from the updated 5-year data of the KEYNOTE-001 trial.

In an interview with&nbsp;Targeted Oncology, Ezzat Elhassadi, MD, discussed the results from this analysis and how the presence of a&nbsp;TP53&nbsp;mutation can impact the survival of patients with MCL. He also highlighted the remaining challenges in this space and how these challenges can be overcome.

The PI3K-delta inhibitor umbralisib demonstrated a favorable toxicity profile as treatment for patients with chronic lymphocytic leukemia who have become intolerant to a prior kinase inhibitor, of either BTK or PI3K inhibition, according to results from a phase II study presented at the 18th International Workshop on CLL.

In an interview with Targeted Oncology, Stacey Stein, MD, discussed what attendees can expect to learn about at the 2019 ISGIO Annual Conference in terms of the treatment landscape for CRC. She also highlighted some of the recent advancements that physicians treating CRC should be aware of heading into this meeting.